| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/13696998.2017.1417312 |
| P698 | PubMed publication ID | 29303621 |
| P2093 | author name string | Liang Wang | |
| Can Chen | |||
| Dechang Chen | |||
| Xianyao Wan | |||
| Jiuhong Wu | |||
| Xiaomeng Yue | |||
| Eliza Kruger | |||
| P2860 | cites work | Bench-to-bedside review: therapeutic management of invasive candidiasis in the intensive care unit | Q21194915 |
| Epidemiology and risk factors for invasive candidiasis | Q27024911 | ||
| Executive Summary: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America | Q28272494 | ||
| Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. | Q33183542 | ||
| Inappropriate empiric antifungal therapy for candidemia in the ICU and hospital resource utilization: a retrospective cohort study | Q33595137 | ||
| Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis | Q34006585 | ||
| Echinocandins: the newest class of antifungals | Q34019188 | ||
| Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? | Q34490092 | ||
| Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing | Q34647337 | ||
| Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance | Q35487439 | ||
| Impact of invasive fungal infection on outcomes of severe sepsis: a multicenter matched cohort study in critically ill surgical patients | Q36642052 | ||
| Association of fluconazole pharmacodynamics with mortality in patients with candidemia | Q36870712 | ||
| Cost-effectiveness of micafungin as an alternative to fluconazole empiric treatment of suspected ICU-acquired candidemia among patients with sepsis: a model simulation | Q37279900 | ||
| Relative frequency of albicans and the various non-albicans Candida spp among candidemia isolates from inpatients in various parts of the world: a systematic review | Q37783462 | ||
| Echinocandin antifungal drugs in fungal infections: a comparison | Q37822777 | ||
| Epidemiology of candidaemia and invasive candidiasis. A changing face | Q38165650 | ||
| Antifungal stewardship in invasive Candida infections | Q38198808 | ||
| Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. | Q38373957 | ||
| Invasive candidiasis in intensive care units in China: Risk factors and prognoses of Candida albicans and non-albicans Candida infections | Q40828130 | ||
| Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature | Q41218000 | ||
| Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. | Q42104395 | ||
| Candidaemia in adult cancer patients: risks for fluconazole-resistant isolates and death | Q43142736 | ||
| De-escalation from micafungin is a cost-effective alternative to traditional escalation from fluconazole in the treatment of patients with systemic Candida infections | Q43415809 | ||
| Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection | Q43438479 | ||
| ESCMID* guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. | Q47643534 | ||
| Invasive candidiasis in intensive care units in China: in vitro antifungal susceptibility in the China-SCAN study. | Q51168224 | ||
| Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial | Q56970523 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | candidiasis | Q273510 |
| fluconazole | Q411478 | ||
| invasive candidiasis | Q29887808 | ||
| P304 | page(s) | 1-15 | |
| P577 | publication date | 2018-01-05 | |
| P1433 | published in | Journal of Medical Economics | Q6295521 |
| P1476 | title | Cost-effectiveness of de-escalation from micafungin versus escalation from fluconazole for invasive candidiasis in China |
| Q54213135 | Appropriate Duration of Intravenous Treatment of Candidemia and Timing of Step Down to Oral Therapy in Non-neutropenic Patients. | cites work | P2860 |
Search more.